Role of Bacillus Clausii in Prevention of Antibiotic Associated Diarrhea in Pediatrics

Antibiotic-associated diarrhea (AAD) occurs when prescribers are compelled to use antimicrobials for appropriate medical indications. Although awareness about AAD has increased during the past 40 years, no single or combined therapy has been found to effectively prevent it or help in rapid recovery from it in the pediatric age group. Therefore, the present interest in probiotics due to the catastrophic effects of the overuse of antibiotics and the need to curtail the problem of AAD in the growing pediatric population. Many probiotics have the potential to be effective for the prevention of AAD, yet the bacterial spore Bacillus clausii stands out among them as the antibiotic can be administered concurrently with the antibiotic therapy. The safety and efficacy profile of Bacillus clausii speak for itself; it is not surprising that it is one of the most common probiotics used in pediatric practice. However, a few doubts linger due to the half-decade of exploitation in clinical work and capsule formulation